AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Platelet factor 4

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

P02776

UPID:

PLF4_HUMAN

Alternative names:

C-X-C motif chemokine 4; Iroplact; Oncostatin-A

Alternative UPACC:

P02776; Q53X61; Q9UC64; Q9UC65

Background:

Platelet factor 4, also known as C-X-C motif chemokine 4, Iroplact, and Oncostatin-A, plays a crucial role in the body's response to injury and inflammation. It is released during platelet aggregation and has a unique ability to neutralize the anticoagulant effects of heparin. This protein is not only a chemotactic agent for neutrophils and monocytes but also a significant inhibitor of endothelial cell proliferation, with its shorter form being more potent.

Therapeutic significance:

Understanding the role of Platelet factor 4 could open doors to potential therapeutic strategies. Its involvement in modulating inflammation and coagulation processes highlights its potential as a target for developing treatments for inflammatory and coagulation disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.